知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.068 秒)

    USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF NEUROPATHIC PAIN
    2.
    发明公开
    USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF NEUROPATHIC PAIN 审中-公开

    公开(公告)号：US20230357378A1

    公开(公告)日：2023-11-09

    申请号：US18301803

    申请日：2023-04-17

    申请人： Neuracle Science Co., Ltd.

    发明人： Bongcheol KIM ,  Dong Sik KIM ,  Soon-gu KWON

    IPC分类号： C07K16/24 ,  A61P25/02

    CPC分类号： C07K16/24 ,  A61P25/02 ,  A61K45/06

    摘要： The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.

    ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF
    10.
    发明申请
    ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF 有权

    公开(公告)号：US20220144932A1

    公开(公告)日：2022-05-12

    申请号：US17290154

    申请日：2019-12-31

    申请人： NEURACLE SCIENCE CO., LTD.

    发明人： Bongcheol KIM ,  Wonkyum KIM ,  Dong Sik KIM ,  Jae-Keun LEE ,  Jeongwon YOON ,  Junho CHUNG ,  Junyeong JIN

    IPC分类号： C07K16/24

    摘要： The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In some embodiments, antibodies are de-immunized to reduce immunogenicity in a human subject. In certain embodiments, antibodies have undergone affinity maturation. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g, inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.